IVERIC bio マネジメント

マネジメント基準チェック /34

IVERIC bioの CEO はGlenn Sblendorioで、 Jul2017年に任命され、の在任期間は 6.17年です。の年間総報酬は$ 9.82Mで、 7.1%給与と92.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.17%を直接所有しており、その価値は$ 9.56M 。経営陣と取締役会の平均在任期間はそれぞれ5.5年と4.6年です。

主要情報

Glenn Sblendorio

最高経営責任者

US$9.8m

報酬総額

CEO給与比率	7.1%
CEO在任期間	6yrs
CEOの所有権	0.2%
経営陣の平均在職期間	5.5yrs
取締役会の平均在任期間	4.6yrs

経営陣の近況

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27

IVERIC bio EPS misses by $0.05

Nov 02

CEO報酬分析

IVERIC bio の収益と比較して、Glenn Sblendorio の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2023	n/a	n/a	-US$223m
Dec 31 2022	US$10m	US$700k	-US$185m
Sep 30 2022	n/a	n/a	-US$159m
Jun 30 2022	n/a	n/a	-US$141m
Mar 31 2022	n/a	n/a	-US$122m
Dec 31 2021	US$6m	US$665k	-US$115m
Sep 30 2021	n/a	n/a	-US$107m
Jun 30 2021	n/a	n/a	-US$108m
Mar 31 2021	n/a	n/a	-US$96m
Dec 31 2020	US$4m	US$640k	-US$85m
Sep 30 2020	n/a	n/a	-US$77m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$2m	US$599k	-US$59m
Sep 30 2019	n/a	n/a	US$63m
Jun 30 2019	n/a	n/a	US$62m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$1m	US$625k	US$63m
Sep 30 2018	n/a	n/a	-US$51m
Jun 30 2018	n/a	n/a	US$153m
Mar 31 2018	n/a	n/a	US$144m
Dec 31 2017	US$3m	US$560k	US$114m
Sep 30 2017	n/a	n/a	US$57m
Jun 30 2017	n/a	n/a	-US$192m
Mar 31 2017	n/a	n/a	-US$200m
Dec 31 2016	US$9m	US$373k	-US$193m

報酬と市場: Glennの総報酬 ($USD 9.82M ) は、 US市場 ($USD 7.74M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Glennの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Glenn Sblendorio (67 yo)

6yrs

在職期間

US$9,816,150

報酬

Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Glenn Sblendorio	CEO & Director	6yrs	US$9.82m	0.17% $ 9.6m
Pravin Dugel	President & Director	2.2yrs	US$4.63m	0.15% $ 8.1m
David Carroll	Senior VP	6.3yrs	US$2.68m	0.032% $ 1.8m
Keith Westby	Senior VP & COO	6.5yrs	US$2.66m	0.029% $ 1.6m
Christopher Simms	Senior VP & Chief Commercial Officer	1.9yrs	US$2.67m	0.024% $ 1.3m
Samir Patel	Co-Founder and Consultant	16.5yrs	データなし	データなし
Xiao-Ping Dai	Chief Technical Officer	2.5yrs	データなし	データなし
Kathy Galante	Senior VP of Investor Relations & Corporate Communications	no data	データなし	データなし
Todd Anderman	Senior VP	5.4yrs	データなし	データなし
Amy Sheehan	Senior VP & Chief Human Resources Officer	5.5yrs	データなし	データなし
Evelyn Harrison	Senior VP & Chief Clinical Operations Officer	7.5yrs	US$411.67k	データなし
Guangping Gao	Chief Strategist of Gene Therapy	3.7yrs	データなし	データなし

5.5yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: ISEEの経営陣は経験豊富で経験豊富です（平均在職期間は5.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Glenn Sblendorio	CEO & Director	6.2yrs	US$9.82m	0.17% $ 9.6m
Pravin Dugel	President & Director	less than a year	US$4.63m	0.15% $ 8.1m
Axel Bolte	Independent Director	15.9yrs	US$354.59k	0.016% $ 882.5k
Adrienne Graves	Independent Chairman of the Board	4.6yrs	US$398.34k	0.016% $ 882.5k
Mark Blumenkranz	Independent Director	3yrs	US$354.59k	0.023% $ 1.3m
Carl Regillo	Member of Scientific Advisory Board	no data	データなし	データなし
Calvin Roberts	Independent Director	4.5yrs	US$365.84k	0.034% $ 1.9m
Jane Pritchett Henderson	Independent Director	5.5yrs	US$385.84k	0.016% $ 882.5k
Anat Lowenstein	Member of Scientific Advisory Board	no data	データなし	データなし
Jeffrey Heier	Member of Scientific Advisory Board	no data	データなし	データなし
Peter Kaiser	Member of Scientific Advisory Board	no data	データなし	データなし
Adnan Tufail	Member of Scientific Advisory Board	no data	データなし	データなし

4.6yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: ISEEの取締役会は経験豊富であると考えられます ( 4.6年の平均在任期間)。

IVERIC bio マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Senior VP & COO exercised options and sold US$730k worth of stock

Senior VP & COO notifies of intention to sell stock

Senior VP exercised options and sold US$2.2m worth of stock

Senior VP notifies of intention to sell stock

Senior VP & COO exercised options and sold US$940k worth of stock

Senior VP & COO exercised options and sold US$299k worth of stock

Recent updates

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Senior VP & COO exercised options and sold US$730k worth of stock

Senior VP & COO notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Senior VP exercised options and sold US$2.2m worth of stock

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Senior VP notifies of intention to sell stock

Senior VP & COO exercised options and sold US$940k worth of stock

Consensus revenue estimates fall by 13%

Senior VP & COO exercised options and sold US$299k worth of stock

No longer forecast to breakeven

Senior VP & COO exercised options and sold US$314k worth of stock

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO notifies of intention to sell stock

CEO & Director exercised options and sold US$350k worth of stock

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO exercised options and sold US$259k worth of stock

Senior VP & COO exercised options to buy US$109k worth of stock.

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

President exercised options to buy US$179k worth of stock.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

Price target increased to US$30.17

Senior VP & COO exercised options and sold US$964k worth of stock

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

Price target increased to US$26.36

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Senior VP & Chief Commercial Officer exercised options and sold US$138k worth of stock

IVERIC bio Q2 2022 Earnings Preview

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

Insider exercised options and sold US$73k worth of stock

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

IVERIC bio: A First Take

Independent Director recently bought US$241k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Price target increased to US$24.38

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Senior VP exercised options and sold US$261k worth of stock

Senior VP notifies of intention to sell stock

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

CEO & Director exercised options and sold US$882k worth of stock

CEO & Director exercised options and sold US$122k worth of stock

Insider recently bought US$50k worth of stock

IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Price target increased to US$16.50

IVERIC Bio, Inc. Provides Updates on Clinical Trails

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Price target increased to US$14.67

IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

マネジメント基準チェック /34